Navigation Links
CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
Date:1/7/2009

Results expected to Support Licensing Activities

VIENNA, Va., Jan. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Alternext US: CVM) announced today the initiation of a definitive study of its new rheumatoid arthritis treatment vaccine (CEL-2000) to determine the long-lasting beneficial effects on animals with the disease. The study is being conducted at the request of a large pharmaceutical company which is evaluating the possibility of acquiring a global license for the vaccine from CEL-SCI. The long-term results, previously presented at the 6th annual GTCbio Vaccine conference, for the CEL-2000 vaccine were better than or comparable to those for Enbrel(R), a leading treatment for people with rheumatoid arthritis.

"We are very excited to see a prominent pharmaceutical company express interest in licensing the vaccine," said Geert Kersten, CEL-SCI's Chief Executive Officer. "As a result of the very good data with this novel approach, we believe that the prospects for licensing the vaccine are promising."

The definitive experiment will confirm the efficacy and durability of the response to the vaccine and will further assess the safety of the CEL-2000 vaccine, in preparation for possible human trials. CEL-2000 may also offer a number of other potential advantages over existing rheumatoid arthritis treatments, such as Enbrel. The data from animal studies of rheumatoid arthritis using CEL-2000 treatment vaccine demonstrated that CEL-2000 is an effective treatment against arthritis with fewer administrations than those required by other anti-rheumatoid arthritis treatments, including Enbrel(R). CEL-2000 is also potentially a more disease type specific therapy is calculated to be significantly less expensive and may be useful in patients unable to tolerate or who may not be responsive to existing anti-arthritis therapies.

Rheumatoid arthritis treatments comp
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
2. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
3. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
4. CEL-SCI Corporation Releases Letter to Shareholders
5. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
6. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
7. Surf Sweets Launches Natural, Organic Candy Line at More Than 250 Toys"R"Us Stores Across the Country
8. ChildRC.com Launches The Child Resource Center
9. First Service Design Firm Launches in United States
10. The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians
11. Florida Breast Augmentation Surgeon Launches State-of-the-Art Website Reflecting his Unique Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Asbury Park, NJ (PRWEB) , ... August 03, ... ... is pleased to announce the development of it’s new program “Designing Secure Healthcare ... provide software architects, engineers and technology leaders from healthcare organizations with access to ...
(Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
(Date:8/2/2015)... ... August 03, 2015 , ... Career Step, an online ... the Association for Healthcare Documentation Integrity’s (AHDI) conference being held in Alexandria, Virginia, ... opportunity the AHDI conference provides us to interact with those in the healthcare ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2
... research by University of Leeds scientists (UK) discovers that a ... bodies to make their own medicine// and there will soon ... Simon Carding of Leeds' Faculty of Biological Sciences has adapted ... a treatment for Inflammatory Bowel Disease (IBD). Bacteria and viruses ...
... dozen people have taken ill and have been hospitalized in ... ‘ baseless’ by spokesman Xiong Yuanda of the Health Bureau ... infectious ‘unknown’ disease, doing the rounds in the city, as ... bureau has sought to dispel reports carried by a famous ...
... scientist, Simon Carding, has genetically altered or designed bacteria ... , The bacterium ; Bacterium ovatus, one of ... to produce human growth factors called cytokines. These were ... damaged by the disease, hence reducing the inflammation. ...
... food allergies are the reasons for many common ailments among ... British residents who have encountered health related issues due to ... it was found out that food intolerance is the root ... intolerance is one of the common forms of food intolerance. ...
... care homes are not being properly attended to in London. As ... in hunger// for most of the time. This was disclosed by ... older people’ campaign Mr. Lewis said that issues during the meal ... is kept far from an old person and nobody is around ...
... an Indian Army officer has become the first person to ... Service//. ,Major S.K. Singh of the Regiment of Artillery ... was declared brain dead at the premier Army Hospital (Research ... statement said. ,The elder Singh was suffering ...
Cached Medicine News:Health News:A Spoonful Of Sugar to 'Switch' the Bacteria on and Off 2Health News:‘Sweet Revenge’ on Inflammatory Bowel Disea 2
(Date:8/2/2015)... THE WOODLANDS, Texas , Aug. 3, 2015 ... today announced that the pivotal TELESTAR Phase 3 ... benefit of oral telotristat etiprate in treating cancer ... controlled by the current standard of care. Telotristat ... on Nobel Prize-winning technology, and is the company,s ...
(Date:7/31/2015)... More than 1,500 substance abuse prevention and ... Indianapolis Aug. 2-6 for Community ... Institute . The week-long training, held at the JW ... our nation,s biggest public health challenges – youth drug ... a one-of-a-kind intensive training opportunity, offering more than 70 ...
(Date:7/31/2015)...  Boston Children,s Hospital physicians report the first ... their anatomy before undergoing high-risk brain procedures. The ... the brain,s blood vessels) that posed special treatment ... Journal of Neurosurgery: Pediatrics , the physicians ... resins to create custom, high-fidelity models of the ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 23D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4
... a,thorough review that concluded late yesterday, the Board ... announced that it,had discontinued the PI-88 phase 3 ... to develop its existing portfolio of compounds and,the ... and,opportunities through Merger & Acquisition activity., The ...
... July 22 Nonin Medical, a leading innovator,of ... has entered,the clinical testing phase with its breakthrough ... application for this,technology is the continuous monitoring of ... oximetry., Early testing data and outcomes from ...
Cached Medicine Technology:Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2
The ENDO CLOSE™ trocar site closure device has application in laparoscopic procedures for approximation of tissues and percutaneous suturing for closing incision sites....
... of a 42" long suture inserted into a ... one end and scored on the other. The ... to a ST-3 needle. The opposite end of ... of the plastic tube. The scored end acts ...
... long ligature inserted into a plastic tube. The plastic ... the other. The suture protrudes from the narrow end ... knot which becomes secure after the device is activated. ... the scored end of the plastic tube. The scored ...
... consists of 18'' long ligature inserted into a plastic ... and scored on the other. The suture protrudes from ... loop with a knot which becomes secure after the ... is fastened to the scored end of the plastic ...
Medicine Products: